

Research Article

Associations between *H19* polymorphisms and neuroblastoma risk in Chinese children

Chao Hu¹, Tianyou Yang², Jing Pan¹,  Jiao Zhang³, Jiliang Yang¹,  Jing He² and  Yan Zou²

¹Department of Pediatric Surgery, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510623, Guangdong, China; ²Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510623, Guangdong, China; ³Department of Pediatric Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China

Correspondence: Yan Zou (378319696@qq.com, monknut@126.com) or Jing He (hejing198374@gmail.com, hejing@gwcmc.org)



Background *H19* polymorphisms have been reported to correlate with an increased susceptibility to a few types of cancers, although their role in neuroblastoma has not yet been clarified.

Materials and methods We investigated the association between three single polymorphisms (rs2839698 G>A, rs3024270 C>G, and rs217727 G>A) and neuroblastoma susceptibility in Chinese Han populations. Three hundred ninety-three neuroblastoma patients and 812 healthy controls were enrolled from the Henan and Guangdong provinces. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to determine the strength of the association of interest.

Results Separated and combined analyses revealed no associations of the rs2839698 G>A, rs3024270 C>G or rs217727 G>A polymorphisms and neuroblastoma susceptibility. In the stratification analysis, female children with rs3024270 GG genotypes had an increased neuroblastoma risk (adjusted OR = 1.61, 95% CI = 1.04–2.50, *P*=0.032).

Conclusion The rs3024270 GG genotype might contribute to an increased neuroblastoma susceptibility in female Chinese children.

Background

Neuroblastoma is the most common malignant extracranial solid tumor in children, accounting for 7–10% of all tumors in children [1,2]. Neuroblastoma originates from neural crest precursor cells of the sympathetic nervous system and is mainly located on the adrenal medulla, paraspinal ganglia, and sympathetic trunk [3–5]. The outcome of neuroblastoma is affected by several factors, such as age of onset, pathology subtypes, International Neuroblastoma Staging System (INSS) stage, *c-Myc* status, DNA ploidy, and structural chromosomal aberrations [3–5].

Genetic factors are critically important in neuroblastoma tumorigenesis. Approximately 1% of patients have a family history of neuroblastoma, and these patients are carriers of certain gene mutations. For example, the anaplastic lymphoma kinase (*ALK*) gene and paired-like homeobox 2b (*PHOX2B*) gene have been identified as predisposing factors to familial neuroblastoma [6–8]. Evidence from genome-wide association studies (GWASs) of sporadic cases also suggests that genetic factors might be involved in the pathogenesis of neuroblastoma [9,10]. These studies indicate an important role of genetic characteristics in the tumorigenesis of neuroblastoma. Single nucleotide polymorphisms (SNPs) or other gene mutations, such as rare mutations in the *ALK* gene at locus 2p23 for familial neuroblastoma, common SNPs in cancer susceptibility candidate 15 (*CASC15*) and neuroblastoma-associated transcript 1 (*NBAT1*) at 6p22 were found to be involved in tumor initiation of neuroblastoma, and the bos taurus BRCA1 associated RING domain 1 (*BARD1*) gene at 2q35, *IL3*, cholesterol-lowering factor (*CFL*), and lens intrinsic membrane (*LIM*) domain only 1 (*LMO1*) were found to be related to the risk of sporadic neuroblastoma.

Received: 09 September 2018
Revised: 23 January 2019
Accepted: 18 March 2019

Accepted Manuscript Online:
19 March 2019
Version of Record published:
05 April 2019

H19 is a paternally imprinted gene that is located at chromosome 11p15.5 near the *IGF2* gene. The expression of *H19* peaks during embryogenesis and is down-regulated after birth in most tissues. Increasing evidence has revealed that *H19* plays a critical role during tumorigenesis. *H19* has been found to re-express during tumorigenesis in many kinds of tumors, such as breast cancer [11], lung cancer [12], invasive cervical carcinomas [13], esophageal cancer [14], and bladder cancer [15]. Smoking, exposure to the carcinogens, nitrosamine and diethylnitrosamine, and hypoxia are risk factors for *H19* overexpression [16]. The up-regulation of *H19* enhances resistance of cancer cells to stress, such as genome destabilization and hypoxia [17].

Recently, a GWAS revealed that SNPs in *H19* are associated with cancer susceptibility [18], and the correlation of *H19* polymorphisms and cancers were confirmed in subsequent studies [19–21]. A study on colorectal cancer reported that the SNPs rs2839698 G>A, rs3024270 C>G, and rs217727 G>A, which are located at exon 1, exon 5, and intron region of the *H19* gene, respectively, have effects on the secondary structure of *H19* [20], and these SNPs were found to be associated with an increased cancer risk in Chinese populations [20,22–27]. However, few studies have focused on neuroblastoma. Herein, we performed a two-center hospital-based case–control study using data from 393 neuroblastoma patients and 812 control subjects to evaluate the association between the *H19* gene rs2839698, rs3024270, and rs217727 polymorphisms and neuroblastoma risk in Chinese children.

Materials and methods

Study subjects

The subjects enrolled were described in previous studies [28,29]. Briefly, a total of 393 neuroblastoma patients and 812 cancer-free controls from two provinces of China were enrolled in the present study. Two hundred seventy-five neuroblastoma patients and 531 controls were recruited from the Guangzhou Women and Children's Medical Center in South China, and 118 neuroblastoma patients and 281 controls were recruited from the Henan province in North China [30,31]. The diagnosis and clinical stages of neuroblastoma were made according to the INSS [32]. The healthy controls had no history of malignancies and were matched to the neuroblastoma cases in terms of age (± 5 years), sex, ethnicity, and geographical region [33–35]. Both neuroblastoma patients and controls were unrelated Chinese Han individuals living in the Guangdong and Henan provinces of China. The present study was approved by the Institutional Review Board of each hospital, and written informed consent was obtained from the participants' parents or legal guardians.

SNP selection and genotyping

The dbSNP database and SNPinfo were used for selecting candidate SNPs. Three widely investigated SNPs (rs2839698, rs3024270, and rs217727) in the *H19* gene were studied. SNP genotyping was performed by the TaqMan real-time PCR system as previously reported [36–40]. To validate the accuracy of the genotyping results from TaqMan real-time PCR, approximately 10% of the samples were randomly selected as quality control samples and genotyped using sequencing. The concordance for the quality control samples was 100%.

Statistical analysis

All statistical tests were two-sided, with a significance level of $P < 0.05$. All statistical analyses were performed using SAS software (version 9.4; SAS Institute, Cary, NC, U.S.A.). Two-sided χ^2 tests were used to analyze the demographic data and genotype frequencies. The Hardy–Weinberg equilibrium was assessed by goodness-of- χ^2 test. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to evaluate associations between *H19* polymorphisms and neuroblastoma susceptibility.

Results

Associations between *H19* gene polymorphisms and neuroblastoma susceptibility

In the present study, 392 patients and 810 controls were successfully genotyped. The genotype frequencies of all the three selected SNPs were in Hardy–Weinberg equilibrium (rs2839698, $P = 0.090$; rs3024270, $P = 0.159$; rs217727, $P = 0.470$). The genotype frequencies of the three SNPs in the patients and controls are listed in Table 1. None of the three SNPs were found to be associated with an increased neuroblastoma risk in the separate analyses of each SNP or in the combined analysis on protective genotypes of the three SNPs.

Table 1 Logistic regression analysis for the associations between *H19* polymorphisms and neuroblastoma risk

Genotype	Cases (n=393)	Controls (n=810)	P ¹	Crude OR (95% CI)	P	Adjusted OR (95% CI) ²	P ²
rs2839698 (HWE = 0.090)							
GG	179 (45.55)	365 (45.06)		1.00		1.00	
AG	175 (44.53)	373 (46.05)		0.96 (0.74–1.23)	0.732	0.96 (0.75–1.24)	0.754
AA	39 (9.92)	72 (8.89)		1.11 (0.72–1.70)	0.650	1.11 (0.73–1.71)	0.624
Additive			0.797	1.01 (0.84–1.22)	0.890	1.02 (0.84–1.23)	0.858
Dominant	214 (54.45)	445 (54.94)	0.874	0.98 (0.77–1.25)	0.874	0.99 (0.77–1.26)	0.901
Recessive	354 (90.08)	738 (91.11)	0.561	1.13 (0.75–1.70)	0.561	1.14 (0.75–1.71)	0.541
rs3024270 (HWE = 0.159)							
CC	99 (25.19)	213 (26.30)		1.00		1.00	
CG	203 (51.65)	424 (52.35)		1.03 (0.77–1.38)	0.842	1.03 (0.77–1.38)	0.829
GG	91 (23.16)	173 (21.36)		1.13 (0.80–1.60)	0.486	1.14 (0.80–1.61)	0.472
Additive			0.764	1.06 (0.89–1.27)	0.494	1.07 (0.89–1.27)	0.480
Dominant	294 (74.81)	597 (73.70)	0.682	1.06 (0.80–1.40)	0.683	1.06 (0.81–1.40)	0.667
Recessive	302 (76.84)	637 (78.64)	0.480	1.11 (0.83–1.48)	0.480	1.11 (0.83–1.48)	0.470
rs217727 (HWE = 0.470)							
GG	186 (47.33)	382 (47.16)		1.00		1.00	
AG	164 (41.73)	342 (42.22)		0.99 (0.76–1.27)	0.907	0.98 (0.76–1.27)	0.888
AA	43 (10.94)	86 (10.62)		1.03 (0.68–1.54)	0.898	1.02 (0.68–1.53)	0.922
Additive			0.979	1.00 (0.84–1.20)	0.970	1.00 (0.84–1.20)	0.997
Dominant	207 (52.67)	428 (52.84)	0.956	0.99 (0.78–1.26)	0.956	0.99 (0.78–1.26)	0.932
Recessive	350 (89.06)	724 (89.38)	0.865	1.03 (0.70–1.52)	0.864	1.03 (0.70–1.52)	0.884
Combined effect of protective genotypes							
0	258 (65.65)	551 (68.02)		1.00		1.00	
1-3	135 (34.35)	259 (31.98)	0.410	1.11 (0.86–1.44)	0.410	1.11 (0.86–1.44)	0.411

¹ χ^2 test for genotype distributions between neuroblastoma patients and cancer-free controls.

²Adjusted for age and sex.

Stratification analysis

We next analyzed the association of the three SNPs with neuroblastoma risk by stratification analyses (Table 2). Stratification analyses were conducted based on age (≤ 18 months, > 18 months), sex (female, male), site of origin (adrenal gland, retroperitoneal, mediastinum, other sites), and clinical stage (I+II+4s, III+IV). We found that the increased risk associated with the rs3024270 GG variant genotype was more pronounced in females (adjusted OR = 1.61, 95% CI = 1.04–2.50, $P=0.032$). Regarding the risk genotypes, no significant associations between the 1–3 risk genotypes and neuroblastoma risk were found.

Discussion

In the present study, we found the *H19* gene rs3024270 C>G polymorphism was associated with neuroblastoma susceptibility in females. This is the first study to report an association between the rs3024270 GG genotype and an increased neuroblastoma risk in female Chinese children in a recessive model.

The association between these SNPs and cancer risk has been studied, while evidence of rs3024270 GG genotype and cancer risk are relatively limited. A study by Li et al. [20] reported an increased risk of colorectal cancer in a Chinese population with the rs3024270 GG genotype. A meta-analysis conducted by Lv et al. [21] investigated the association between long noncoding RNA polymorphisms and cancer risk, and the rs3024270 C>G polymorphism was reported to be correlated with an overall cancer risk. However, another study found a decreased risk of invasive bladder cancer in patients with the rs3024270 CC genotype in the Chinese population [41]. Besides the rs3024270 C>G polymorphism, a series of studies reported the role of the rs2839698 G>A polymorphism in platinum-based chemotherapy response in lung cancer [42], colorectal cancer [20], gastric cancer [24] and rheumatoid arthritis [22]. The rs217727 G>A polymorphism was also reported to be associated with a risk of oral squamous cell carcinoma [19], osteosarcoma [43], bladder cancer [44], cervical cancer of the squamous carcinomas subtype [20], and breast cancer [27]. Our study provides new evidence that the rs3024270 C>G polymorphism in the *H19* gene might be involved in the development of neuroblastoma.

Table 2 Stratification analysis for association between H19 genotypes and neuroblastoma susceptibility

Variables	rs2839698 (pa- tient/control)		Adjusted OR ¹ (95% CI)	P ¹	rs3024270 (pa- tient/control)		Adjusted OR ¹ (95% CI)	P ¹	rs217727 (pa- tient/control)		Adjusted OR ¹ (95% CI)	P ¹	Risk genotypes (patient/control)		Adjusted OR ¹ (95% CI)	P ¹	
	GG/AG	AA			CC/CG	GG			GG/AG	AA			0	1-3			
Age, months																	
≤18	110/276	15/29	1.29 (0.66–2.50)	0.452	95/240	31/65	1.21 (0.74–1.97)	0.454	116/270	10/35	0.67 (0.32–1.39)	0.278	85/205	41/100	0.99 (0.64–1.54)	0.962	
>18	243/462	24/43	1.06 (0.63–1.79)	0.830	207/397	60/108	1.07 (0.75–1.52)	0.727	234/454	33/51	1.25 (0.79–2.00)	0.342	173/346	94/159	1.18 (0.86–1.62)	0.297	
Sex																	
Female	148/317	20/24	1.79 (0.96–3.34)	0.068	123/278	45/63	1.61 (1.04–2.50)	0.032	152/302	16/39	0.83 (0.45–1.53)	0.546	107/239	61/102	1.35 (0.91–1.99)	0.137	
Male	206/421	19/48	0.83 (0.48–1.45)	0.516	179/359	46/110	0.85 (0.57–1.25)	0.398	198/422	27/47	1.22 (0.74–2.02)	0.442	151/312	74/157	0.98 (0.70–1.37)	0.899	
Sites of origin																	
Adrenal gland	140/738	13/72	0.97 (0.52–1.80)	0.915	115/637	38/173	1.23 (0.82–1.84)	0.327	133/724	20/86	1.24 (0.73–2.08)	0.430	94/551	59/259	1.33 (0.93–1.90)	0.122	
Retroperitoneal	79/738	8/72	1.01 (0.47–2.18)	0.982	67/637	20/173	1.08 (0.64–1.83)	0.776	82/724	5/86	0.52 (0.21–1.32)	0.169	62/551	25/259	0.85 (0.52–1.39)	0.516	
Mediastinum	98/738	11/72	1.16 (0.59–2.27)	0.661	89/637	20/173	0.84 (0.50–1.40)	0.493	95/724	14/86	1.25 (0.68–2.28)	0.478	75/551	34/259	0.97 (0.63–1.50)	0.901	
Others	30/738	6/72	2.00 (0.81–4.99)	0.135	24/637	12/173	1.82 (0.89–3.73)	0.100	34/724	2/86	0.50 (0.12–2.13)	0.350	22/551	14/259	1.35 (0.68–2.69)	0.391	
Clinical stage																	
I+II+4s	146/738	16/72	1.13 (0.64–2.00)	0.677	126/637	36/173	1.06 (0.70–1.59)	0.792	143/724	19/86	1.13 (0.66–1.91)	0.661	107/551	55/259	1.10 (0.77–1.57)	0.602	
III+IV	190/738	21/72	1.17 (0.70–1.95)	0.561	160/637	51/173	1.19 (0.83–1.71)	0.335	187/724	24/86	1.06 (0.65–1.71)	0.821	135/551	76/259	1.20 (0.87–1.65)	0.259	

¹Adjusted for age and sex.
 Values in bold indicate $P < 0.05$.

SNPs studied in our research are all located in the *H19* gene and were reported to have an impact on the folding structure of *H19* [20], which may affect the expression or functions of H19. The role of H19 in cancers has been widely studied. The *H19* gene is an imprinted oncofetal gene that is located on chromosome 11p15.5 near the *IGF2* gene locus [45]. Wada et al. [46] reported a maintenance of normal imprinting of the *H19* and *IGF2* genes in neuroblastoma. The expression of H19 was significantly up-regulated in hepatic metastases of several types of cancers [47]. Growing evidence indicates that H19 is involved in both the proliferation and differentiation processes of cancer cells. H19 promotes cell cycle progression in breast cancer, while the depletion of *H19* RNA arrests breast cancer cells in the pre-S-phase of the cell cycle [48]. The knockdown of H19 inhibits the growth of HCC and gastric cancer cells under hypoxic recovery conditions [49].

The mechanisms by which these SNPs regulate H19 expression and are involved in cancer are unclear. A possible explanation is that SNPs may affect *H19* gene expression and function. It was reported that rs3024270 C>G, rs2839698 G>A, and rs217727 G>A dramatically altered the secondary structure of H19, and the rs3024270 GG genotype was associated with an increased risk of colorectal cancer in a Chinese population. H19 was found to act as a primary microRNA precursor, and H19 expression regulated specific mRNAs via post transcription [53]. Liang et al. [54] reported that lncRNA H19 modulated the expression of multiple genes involved in colorectal cancer by acting as a competing endogenous RNA, and H19 was also reported to produce antisense 91H, which increased the stability in cancer cells, leading to the accumulation of 91H in cancer cell lines and breast cancer tissues [55]. SNPs located in the introns and exons of the *H19* gene might change the promoter activity and function of H19 by the alteration of target miRNAs, such as hsa-miR-24-1-5p, hsa-miR-4486, and hsa-miR-566 [55]. Additionally, H19 was also found to interact with other tumor suppressor genes, such as *p53* and *c-Myc*. Increased expression of H19 during hypoxic conditions was found in cell lines with a mutant *p53* gene but not in cells with wild-type *p53* gene [50], and overexpression of H19 partially suppressed *p53* activation in gastric cancer cells [51]. H19 expression was activated by *c-Myc* via direct binding to the regulatory region of the *H19* gene [52].

In our study, we found the GG allele pattern in 45/63 female NB patients and in 46/110 male NB patients. In the stratification analysis based on sex, disequilibrium of the G allele and the C allele was found. *H19* is an imprinted gene that is expressed from the maternal chromosome, but not the paternal chromosome [45]. This fact might partly explain the apparent disequilibrium of the analyzed SNPs. In the stratified analysis, no relation of H19 SNPs with the susceptibility of neuroblastoma patients, the origin of the tumor and the clinical stage of the tumor were found. In other studies, no relationship between rs3024270 and the susceptibility of cancer was found in stratified analyses, including age, sex, smoking, drinking etc. Further studies with larger sample sizes of patients with neuroblastoma and other tumors may provide more information.

There are several limitations of this case-control study. First, a potential selection bias would be induced because the enrollment of cases and controls occurred in a hospital. Therefore, further studies with larger populations would be of great value. Second, only three SNPs in the *H19* were included in the current study, and other polymorphisms, such as rs2735971 C>T, were not included. Furthermore, the biological functions of the three SNPs are not clear, so functional studies are needed to provide more evidence. The sample size is relatively small in the present study due to the difficulty in sample collection. We will continue our study on neuroblastoma and update the results in further study.

Conclusion

In the present study, we reported the relationship between the rs3024270 GG genotype and the increased susceptibility of neuroblastoma in female Chinese children. Further functional studies on rs3024270 and studies with larger populations and different ethnicities would be valuable to clarify the role of *H19* SNPs in neuroblastoma.

Author contribution

C.H. and T.Y. made substantial contributions to conception and design of the present study. J.P., J.Z., and J.Y. made substantial contribution to the acquisition and interpretation of data. C.H. made substantial contribution to statistical analysis and interpretation of data. J.H. and Y.Z. had been involved in drafting the manuscript and revising it critically for important intellectual content. Y.Z. and J.H. agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. C.H. and T.Y. contributed to the work equally. All authors had given final approval of the version to be published.

Data availability

The data used to support the findings of the present study are available from the corresponding authors upon request.

Competing interests

The authors declare that there are no competing interests associated with the manuscript.

Funding

This work was supported by the Pearl River S&T Nova Programme of Guangzhou [grant number 201710010086]; and the State Clinical Key Specialty Construction Project (Paediatric Surgery) 2013 [grant number GJLCZD1301].

Abbreviations

ALK, anaplastic lymphoma kinase; CI, confidence interval; GWAS, genome-wide association study; INSS, International Neuroblastoma Staging System; OR, odds ratio; SNP, single nucleotide polymorphism.

References

- 1 Brodeur, G.M. (2003) Neuroblastoma: biological insights into a clinical enigma. *Nat. Rev. Cancer* **3**, 203–216, <https://doi.org/10.1038/nrc1014>
- 2 Kamijo, T. and Nakagawara, A. (2012) Molecular and genetic bases of neuroblastoma. *Int. J. Clin. Oncol.* **17**, 190–195, <https://doi.org/10.1007/s10147-012-0415-7>
- 3 Bagatell, R. et al. (2009) Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database. *J. Clin. Oncol.* **27**, 365–370, <https://doi.org/10.1200/JCO.2008.17.9184>
- 4 Cohn, S.L. et al. (2009) The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. *J. Clin. Oncol.* **27**, 289–297, <https://doi.org/10.1200/JCO.2008.16.6785>
- 5 Monclair, T. et al. (2009) The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. *J. Clin. Oncol.* **27**, 298–303, <https://doi.org/10.1200/JCO.2008.16.6876>
- 6 Trochet, D. et al. (2005) PHOX2B genotype allows for prediction of tumor risk in congenital central hypoventilation syndrome. *Am. J. Hum. Genet.* **76**, 421–426, <https://doi.org/10.1086/428366>
- 7 McConville, C. et al. (2006) PHOX2B analysis in non-syndromic neuroblastoma cases shows novel mutations and genotype-phenotype associations. *Am. J. Med. Genet. A* **140**, 1297–1301, <https://doi.org/10.1002/ajmg.a.31278>
- 8 Mosse, Y.P. et al. (2008) Identification of ALK as a major familial neuroblastoma predisposition gene. *Nature* **455**, 930–935, <https://doi.org/10.1038/nature07261>
- 9 Caren, H. et al. (2008) High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. *Biochem. J.* **416**, 153–159, <https://doi.org/10.1042/BJ20081834>
- 10 George, R.E. et al. (2008) Activating mutations in ALK provide a therapeutic target in neuroblastoma. *Nature* **455**, 975–978, <https://doi.org/10.1038/nature07397>
- 11 Lottin, S. et al. (2002) Overexpression of an ectopic H19 gene enhances the tumorigenic properties of breast cancer cells. *Carcinogenesis* **23**, 1885–1895, <https://doi.org/10.1093/carcin/23.11.1885>
- 12 Kondo, M. et al. (1995) Frequent loss of imprinting of the H19 gene is often associated with its overexpression in human lung cancers. *Oncogene* **10**, 1193–1198
- 13 Douc-Rasy, S. et al. (1996) High incidence of loss of heterozygosity and abnormal imprinting of H19 and IGF2 genes in invasive cervical carcinomas. Uncoupling of H19 and IGF2 expression and biallelic hypomethylation of H19. *Oncogene* **12**, 423–430
- 14 Hibi, K. et al. (1996) Loss of H19 imprinting in esophageal cancer. *Cancer Res.* **56**, 480–482
- 15 Ariel, I. et al. (1995) The imprinted H19 gene as a tumor marker in bladder carcinoma. *Urology* **45**, 335–338, [https://doi.org/10.1016/0090-4295\(95\)80030-1](https://doi.org/10.1016/0090-4295(95)80030-1)
- 16 Matouk, I.J. et al. (2007) The H19 non-coding RNA is essential for human tumor growth. *PLoS ONE* **2**, e845, <https://doi.org/10.1371/journal.pone.0000845>
- 17 Yang, B. et al. (2014) A novel pathway links oxidative stress to loss of insulin growth factor-2 (IGF2) imprinting through NF-kappaB activation. *PLoS ONE* **9**, e88052, <https://doi.org/10.1371/journal.pone.0088052>
- 18 Fanale, D. et al. (2012) Breast cancer genome-wide association studies: there is strength in numbers. *Oncogene* **31**, 2121–2128, <https://doi.org/10.1038/ncr.2011.408>
- 19 Guo, Q.Y., Wang, H. and Wang, Y. (2017) LncRNA H19 polymorphisms associated with the risk of OSCC in Chinese population. *Eur. Rev. Med. Pharmacol. Sci.* **21**, 3770–3774
- 20 Li, S. et al. (2016) Association of genetic variants in lncRNA H19 with risk of colorectal cancer in a Chinese population. *Oncotarget* **7**, 25470–25477, <https://doi.org/10.18632/oncotarget.13402>
- 21 Lv, Z., Xu, Q. and Yuan, Y. (2017) A systematic review and meta-analysis of the association between long non-coding RNA polymorphisms and cancer risk. *Mutat. Res.* **771**, 1–14, <https://doi.org/10.1016/j.mrrev.2016.10.002>
- 22 Zhou, J.Z. et al. (2017) A study on associations of single-nucleotide polymorphisms within H19 and HOX transcript antisense RNA (HOTAIR) with genetic susceptibility to rheumatoid arthritis in a Chinese population. *Inflamm. Res.* **66**, 515–521, <https://doi.org/10.1007/s00011-017-1035-5>
- 23 Yang, M.L. et al. (2018) The association of polymorphisms in lncRNA-H19 with hepatocellular cancer risk and prognosis. *Biosci. Rep.* **38**, BSR20171652, <https://doi.org/10.1042/BSR20171652>
- 24 Yang, C. et al. (2015) Tag SNPs in long non-coding RNA H19 contribute to susceptibility to gastric cancer in the Chinese Han population. *Oncotarget* **6**, 15311–15320

- 25 Wang, W. et al. (2018) The rs2839698 single nucleotide polymorphism of lncRNA H19 is associated with post-operative prognosis in T3 gastric adenocarcinoma. *Clin. Lab.* **64**, 105–112, <https://doi.org/10.7754/Clin.Lab.2017.170706>
- 26 Verhaegh, G.W. et al. (2008) Polymorphisms in the H19 gene and the risk of bladder cancer. *Eur. Urol.* **54**, 1118–1126, <https://doi.org/10.1016/j.eururo.2008.01.060>
- 27 Lin, Y. et al. (2017) Genetic variants in long noncoding RNA H19 contribute to the risk of breast cancer in a southeast China Han population. *Oncotargets Ther.* **10**, 4369–4378, <https://doi.org/10.2147/OTT.S127962>
- 28 He, J. et al. (2018) Association of common genetic variants in pre-microRNAs and neuroblastoma susceptibility: a two-center study in Chinese children. *Mol. Ther. Nucleic Acids*, <https://doi.org/10.1016/j.omtn.2018.01.003>
- 29 Zhang, Z. et al. (2018) LINC00673 rs11655237 C>T confers neuroblastoma susceptibility in Chinese population. *Biosci. Rep.* **38**, BSR20171667, <https://doi.org/10.1042/BSR20171667>
- 30 Zhang, J. et al. (2017) LMO1 polymorphisms reduce neuroblastoma risk in Chinese children: a two-center case-control study. *Oncotarget* **8**, 65620–65626
- 31 Zhang, J. et al. (2017) CASC15 gene polymorphisms reduce neuroblastoma risk in Chinese children. *Oncotarget* **8**, 91343–91349
- 32 Brodeur, G.M. et al. (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. *J. Clin. Oncol.* **11**, 1466–1477, <https://doi.org/10.1200/JCO.1993.11.8.1466>
- 33 He, J. et al. (2016) Association of potentially functional variants in the XPG gene with neuroblastoma risk in a Chinese population. *J. Cell. Mol. Med.* **20**, 1481–1490, <https://doi.org/10.1111/jcmm.12836>
- 34 He, J. et al. (2017) The TP53 gene rs1042522 C>G polymorphism and neuroblastoma risk in Chinese children. *Aging* **9**, 852–859
- 35 He, J. et al. (2017) Genetic variations of GWAS-identified genes and neuroblastoma susceptibility: a replication study in Southern Chinese children. *Transl. Oncol.* **10**, 936–941, <https://doi.org/10.1016/j.tranon.2017.09.008>
- 36 He, J. et al. (2012) Polymorphisms in the XPG gene and risk of gastric cancer in Chinese populations. *Hum. Genet.* **131**, 1235–1244, <https://doi.org/10.1007/s00439-012-1152-8>
- 37 Gong, J. et al. (2018) A polymorphic MYC response element in KBTBD11 influences colorectal cancer risk, especially in interaction with a MYC regulated SNP rs6983267. *Ann. Oncol.* **29**, 632–639, <https://doi.org/10.1093/annonc/mdx789>
- 38 Li, J. et al. (2017) A low-frequency variant in SMAD7 modulates TGF-beta signaling and confers risk for colorectal cancer in Chinese population. *Mol. Carcinog.* **56**, 1798–1807, <https://doi.org/10.1002/mc.22637>
- 39 Lou, J. et al. (2017) A functional polymorphism located at transcription factor binding sites, rs6695837 near LAMC1 gene, confers risk of colorectal cancer in Chinese populations. *Carcinogenesis* **38**, 177–183
- 40 Zou, D. et al. (2018) Integrative expression quantitative trait locus-based analysis of colorectal cancer identified a functional polymorphism regulating SLC22A5 expression. *Eur. J. Cancer* **93**, 1–9, <https://doi.org/10.1016/j.ejca.2018.01.065>
- 41 Li, Z. and Niu, Y. (2018) Association between lncRNA H19 (rs217727, rs2735971 and rs3024270) polymorphisms and the risk of bladder cancer in Chinese population. *Minerva Urol. Nefrol.*, [Epub ahead of print], <https://doi.org/10.23736/S0393-2249.18.03004-7>
- 42 Gong, W.J. et al. (2016) Association of well-characterized lung cancer lncRNA polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response. *Tumour Biol.* **37**, 8349–8358, <https://doi.org/10.1007/s13277-015-4497-5>
- 43 He, T.D. et al. (2017) Association between H19 polymorphisms and osteosarcoma risk. *Eur. Rev. Med. Pharmacol. Sci.* **21**, 3775–3780
- 44 Hua, Q. et al. (2016) Genetic variants in lncRNA H19 are associated with the risk of bladder cancer in a Chinese population. *Mutagenesis* **31**, 531–538, <https://doi.org/10.1093/mutage/gew018>
- 45 Ayesh, S. et al. (2002) Possible physiological role of H19 RNA. *Mol. Carcinog.* **35**, 63–74, <https://doi.org/10.1002/mc.10075>
- 46 Wada, M. et al. (1995) Maintenance of normal imprinting of H19 and IGF2 genes in neuroblastoma. *Cancer Res.* **55**, 3386–3388
- 47 Fellig, Y. et al. (2005) H19 expression in hepatic metastases from a range of human carcinomas. *J. Clin. Pathol.* **58**, 1064–1068, <https://doi.org/10.1136/jcp.2004.023648>
- 48 Berteaux, N. et al. (2005) H19 mRNA-like noncoding RNA promotes breast cancer cell proliferation through positive control by E2F1. *J. Biol. Chem.* **280**, 29625–29636, <https://doi.org/10.1074/jbc.M504033200>
- 49 Matouk, I. et al. (2004) Oncofetal splice-pattern of the human H19 gene. *Biochem. Biophys. Res. Commun.* **318**, 916–919, <https://doi.org/10.1016/j.bbrc.2004.04.117>
- 50 Matouk, I.J. et al. (2010) The oncofetal H19 RNA connection: hypoxia, p53 and cancer. *Biochim. Biophys. Acta* **1803**, 443–451, <https://doi.org/10.1016/j.bbamcr.2010.01.010>
- 51 Yang, F. et al. (2012) Up-regulated long non-coding RNA H19 contributes to proliferation of gastric cancer cells. *FEBS J.* **279**, 3159–3165, <https://doi.org/10.1111/j.1742-4658.2012.08694.x>
- 52 Barsyte-Lovejoy, D. et al. (2006) The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis. *Cancer Res.* **66**, 5330–5337, <https://doi.org/10.1158/0008-5472.CAN-06-0037>
- 53 Cai, X. and Cullen, B.R. (2007) The imprinted H19 noncoding RNA is a primary microRNA precursor. *RNA* **13**, 313–316, <https://doi.org/10.1261/rna.351707>
- 54 Liang, W.C. et al. (2015) The lncRNA H19 promotes epithelial to mesenchymal transition by functioning as miRNA sponges in colorectal cancer. *Oncotarget* **6**, 22513–22525, <https://doi.org/10.18632/oncotarget.4154>
- 55 Berteaux, N. et al. (2008) A novel H19 antisense RNA overexpressed in breast cancer contributes to paternal IGF2 expression. *Mol. Cell. Biol.* **28**, 6731–6745, <https://doi.org/10.1128/MCB.02103-07>